The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Addressing the unmet need for patients with lenalidomide-refractory multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses strategies to address the unmet needs of patients with lenalidomide-refractory multiple myeloma (MM). He highlights combination therapies like selinexor with bortezomib and dexamethasone, and belantamab mafodotin, which is under investigation in the DREAMM-7 (NCT04246047) and DREAMM-8 (NCT04484623) trials. Additionally, he emphasizes the importance of genomic profiling for each patient to advance personalized medicine. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Sanofi, GSK, Janssen, BMS-Celgene, Takeda and Karyopharm.
